Security key
92840H400
Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN)
CUSIP: 92840H400
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 47,610
- Total 13F value
- $10,760
- Share change
- +47,610
- SEC-reported price per share
- $0.23
- Number of holders
- 2
- Value change
- +$10,760
- Number of buys
- 2
- Shares outstanding
- 41,041,331
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
2
Top holders
2
VTGN full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Vistagen Therapeutics, Inc. SEC filings
Vistagen Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 92840H400
Recent filing periods:
Ownership snapshot
Top reported holders of VTGN - Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TCG Crossover GP II, LLC
Disclosed value leader
BIOTECHNOLOGY VALUE FUND L P
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 10%
13D/G row: TCG Crossover GP II, LLC
Showing 1-6 of 15 holder rows.
Quick read
TCG Crossover GP II, LLC leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens TCG Crossover GP II, LLC's linked filing trail.
Comparable ownership
Top 5
TCG Crossover GP II, LLC
10%
BIOTECHNOLOGY VALUE FUND L P
10%
Commodore Capital LP
9.9%
GREAT POINT PARTNERS LLC
5%
Nantahala Capital Management, LLC
4.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TCG Crossover GP II, LLC |
13D/G
Chen Yu
|
10%
|
$2,343,167
4,100,029 shares
|
$0 | 31 Mar 2026 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
10%
|
$7,217,318
3,084,324 shares
|
$0 | 31 Dec 2024 |
| Commodore Capital LP |
13D/G
3/4/5
10%+ Owner
|
9.9%
|
$3,243,796
4,383,508 shares
|
$0 | 31 Dec 2025 |
| GREAT POINT PARTNERS LLC |
13D/G
|
5%
|
$1,521,317
2,055,834 shares
|
$0 | 31 Dec 2025 |
| Nantahala Capital Management, LLC |
13D/G
|
4.7%
|
$1,445,253
1,953,045 shares
|
-$912,064 | 31 Dec 2025 |
| VANGUARD GROUP INC |
13D/G
The Vanguard Group
|
4.6%
|
$1,240,822
1,824,738 shares
|
+$93,162 | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
2
Shares
47,610
Rows available
2
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
53
Q2 2026 holders
2
Holder diff
-51
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend